XML 48 R28.htm IDEA: XBRL DOCUMENT v3.3.1.900
Quarterly Consolidated Financial Data (Unaudited) (Tables)
12 Months Ended
Dec. 31, 2015
Quarterly Consolidated Financial Data (Unaudited)  
Schedule of unaudited quarterly consolidated financial data

 

 

 

Quarter Ended

 

 

 

March 31,

 

June 30,

 

September 30,

 

December 31,

 

 

 

2015

 

2015

 

2015

 

2015

 

 

 

(dollars in thousands, except share and per share data)

 

Revenues

 

$

 

$

 

$

 

$

 

 

 

 

 

 

 

 

 

 

 

Costs and Expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

18,198

 

19,525

 

20,424

 

19,881

 

Purchased in-process research and development

 

 

 

 

 

Selling, general and administrative

 

4,606

 

7,394

 

2,728

 

7,066

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

(22,804

)

(26,919

)

(23,152

)

(26,947

)

Other Income /(Loss):

 

 

 

 

 

 

 

 

 

Interest and investment income/(expense), net

 

(4,317

)

(5,207

)

(4,291

)

(3,469

)

Tax credits

 

 

 

 

 

Change in fair value of derivative instruments—warrants

 

(268

)

(1,542

)

1,446

 

(30

)

 

 

 

 

 

 

 

 

 

 

Total Other (Loss)/ Income

 

(4,585

)

(6,749

)

(2,845

)

(3,499

)

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(27,389

)

$

(33,668

)

$

(25,997

)

$

(30,446

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding—basic and diluted (a)

 

96,683,525

 

100,343,637

 

111,328,339

 

113,678,306

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss per Common Share—basic and diluted (a)

 

$

(0.28

)

$

(0.34

)

$

(0.23

)

$

(0.27

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.

 

 

 

Quarter Ended

 

 

 

March 31,
2014

 

June 30,
2014

 

September 30,
2014

 

December 31,
2014

 

 

 

(dollars in thousands, except share and per share data)

 

Revenues

 

$

 

$

 

$

 

$

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Research and Development

 

13,299

 

24,479

 

20,946

 

24,550

 

Purchased in-process research and development

 

 

 

 

 

 

General and administrative

 

3,178

 

2,279

 

2,506

 

3,041

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

(16,477

)

(26,758

)

(23,452

)

(27,591

)

 

 

 

 

 

 

 

 

 

 

Other income

 

 

 

 

 

 

 

 

 

Amortization of deferred financing costs

 

 

 

 

(411

)

Interest and investment income/(expense), net(includes interest expense of $2,500 on Senior Convertible Debentures for year 2014)

 

29

 

(1

)

19

 

(2,511

)

Tax credits

 

 

83

 

 

 

Change in fair value of derivative instruments—warrants

 

223

 

756

 

425

 

(42

)

 

 

 

 

 

 

 

 

 

 

Total other income/(loss)

 

252

 

838

 

444

 

(2,964

)

Net Loss

 

$

(16,225

)

$

(25,920

)

$

(23,008

)

(30,555

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic and diluted (a)

 

92,056,124

 

94,069,703

 

94,738,048

 

96,190,332

 

 

 

 

 

 

 

 

 

 

 

Net loss per Common Share, basic and diluted(a):

 

$

(0.18

)

$

(0.28

)

$

(0.24

)

(0.32

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.